Key result
Non-vitamin K antagonist oral anticoagulants are widely considered the antithrombotic of choice for stroke prevention in patients with atrial fibrillation and EHRA type 2 valvular heart disease.
This editorial highlights the evolving landscape of antithrombotic choice in atrial fibrillation, emphasizing the use of NOACs for EHRA type 2 valvular AF and the need for individualized bleeding risk assessment in patients with concomitant coronary heart disease.
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the UK affecting 1.3 million people. AF is particularly common in older people, with one in ten over the age of 75 years affected. The prevalence of AF is projected to increase with improved survival of patients from chronic cardiac disorders that predispose to AF, such as coronary heart disease. AF increases the risk of stroke fivefold due to thromboembolism and cause 15% of all strokes.
No takes yet. Share an insight, caveat, or question.
Mustafa et al. (2020) conducted an editorial in Atrial fibrillation. Antithrombotics was evaluated. Non-vitamin K antagonist oral anticoagulants are widely considered the antithrombotic of choice for stroke prevention in patients with atrial fibrillation and EHRA type 2 valvular heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: